Glenvog 1mg/500mg/0.2mg Tablet SR
Marketer
Astonea Labs Private Limited
Salt Composition
Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.2mg)
Overview Glenvog 1mg/500mg/0.2mg Tablet SR
Diabeticaid SR tablets (1mg/500mg/0.2mg) are an anti-diabetic combination medication for adult type 2 diabetes. This formulation helps regulate blood glucose. Diabeticaid SR should be ingested with food, consistently at the same time daily for optimal effectiveness. Dosage is determined by your physician and may be adjusted based on your blood sugar readings. Continued use is crucial; discontinuation without medical guidance risks elevated blood sugar, potentially leading to kidney complications, vision impairment, neuropathy, and limb loss. Remember, Diabeticaid SR complements a comprehensive diabetes management plan including diet, exercise, and weight management as directed by your doctor. Hypoglycemia (low blood sugar) is a common side effect. Learn to recognize its symptoms – sweating, dizziness, headache, tremors – and know how to treat it. Maintain regular mealtimes and always carry a rapid-acting glucose source (e.g., sugary snacks or juice). Alcohol consumption should be minimized due to its potential to worsen hypoglycemia. Other potential side effects include altered taste, nausea, diarrhea, abdominal discomfort, headache, swelling, blurred vision, bone fractures, and upper respiratory infections. Weight gain is also possible. This medication is contraindicated for those with type 1 diabetes, diabetic ketoacidosis, or severe hepatic or renal impairment. Individuals with a history of heart disease should inform their doctor before commencing treatment. Pregnant or lactating women require medical consultation prior to use. Regular blood glucose monitoring is essential, along with potential blood tests to monitor blood cell counts and liver function as directed by your physician.
Primary Ingredients of Glenvog 1mg/500mg/0.2mg Tablet SR
No information provided. Please provide the text you wish to be rewritten.
Uses of Glenvog 1mg/500mg/0.2mg Tablet SR
Managing Type 2 Diabetes
Major Benefits of Glenvog 1mg/500mg/0.2mg Tablet SR:
Consume this medication precisely as prescribed by your physician, adhering to the specified dosage and treatment period. Ingest the Glenvog 1mg/500mg/0.2mg Tablet SR whole; avoid chewing, crushing, or fracturing. Administer on an empty stomach.
Common Side effects of Glenvog 1mg/500mg/0.2mg Tablet SR:
- Nausea
- Diarrhea
- Abdominal pain
- Hypoglycemia (low blood glucose level)
- Loss of appetite
How to use Glenvog 1mg/500mg/0.2mg Tablet SR:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment period. Ingest the Glenvog 1mg/500mg/0.2mg Tablet SR whole; avoid chewing, crushing, or fracturing it. Administer this medication on an empty stomach.
How Glenvog 1mg/500mg/0.2mg Tablet SR works:
Glenvog SR tablets (1mg/500mg/0.2mg) contain a triple-action antidiabetic formulation.
SAFETY ADVICE
AlcoholUNSAFE
Concurrent alcohol use with Glenvog 1mg/500mg/0.2mg SR tablets is inadvisable.
PregnancyCONSULT YOUR DOCTOR
The extended-release Glenvog tablet (1mg/500mg/0.2mg) might pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the potential advantages against any hazards before recommending its use. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
The extended-release Glenvog tablet (1mg/500mg/0.2mg) is likely unsafe for breastfeeding mothers. Available human data indicates potential transfer to breast milk, posing a risk to the infant.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.
KidneyUNSAFE
The use of Glenvog 1mg/500mg/0.2mg Tablet SR is inadvisable for individuals with kidney impairment and should be omitted. A physician's consultation is recommended. Its use is particularly discouraged in patients experiencing severe kidney dysfunction.
LiverCAUTION
Patients with liver impairment should use Glenvog 1mg/500mg/0.2mg SR tablets cautiously. Dosage modification may be necessary for these individuals. Medical advice is recommended. A reduced initial dose is typically prescribed for patients with mild to moderate hepatic dysfunction; Glenvog 1mg/500mg/0.2mg SR tablets are unsuitable for those with severe liver disease.
What if you forget to take Glenvog 1mg/500mg/0.2mg Tablet SR :
Should you forget a dose of Glenvog 1mg/500mg/0.2mg Extended-Release Tablet, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Glenvog 1mg/500mg/0.2mg Tablet SR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Type of Treatment | Diabetes Management |
3,018 People bought this recently